Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: Results of an 8-week double-blind randomized controlled trial

Schizophrenia Bulletin

Volumn 37, Issue 2, 2011, Pages 352-361

  Grootens, K P ^a,d   Van Veelen, N M J ^b   Peuskens, J ^e   Sabbe, B G C ^c   Thys, E ^c   Buitelaar, J K ^a   Verkes, R J ^a   Kahn, R S ^b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e NONE

Author keywords

antipsychotics; metabolic syndrome; schizophrenia; schizophreniform disorder

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CHOLESTEROL; GLUCOSE; LITHIUM; OLANZAPINE; PROLACTIN; PROPRANOLOL; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEBEPHRENIA; HEINRICH QUALITY OF LIFE SCALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; ONSET AGE; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESIDUAL SCHIZOPHRENIA; SAMPLE SIZE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; ALANINE TRANSAMINASE; ANTIPSYCHOTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BIPERIDEN; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CHRONIC DISEASE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TRIGLYCERIDES; YOUNG ADULT;

EID: 79952169014     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp037     Document Type: Article

References (30)

1. Leucht S, Barnes T R E, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222. (Pubitemid 41070936)
2. Picchioni MM, Murray RM. Schizophrenia. BMJ. 2007;335:91-95. (Pubitemid 47123289)
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
4. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull. 2005;31:705-722. (Pubitemid 41253320)
5. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005; CD001359.
6. Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUt LASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry. 2006;63:1069-1072. (Pubitemid 44498385)
7. Bagnall A, Lewis RA, Leitner ML, Kleijnen J. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000; CD001945.
8. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879-1887. (Pubitemid 41428617)
9. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535-1538. (Pubitemid 41105572)
10. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837-1847. (Pubitemid 39314678)
11. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-1097. (Pubitemid 351418005)
12. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580-588. (Pubitemid 36618289)
13. Stroup TS, Lieberman JA, McEvoy JP. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611-622. (Pubitemid 44464570)
14. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78:147-156. (Pubitemid 41254018)
15. Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev. 2003; CD004410.
16. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549. (Pubitemid 29162974)
17. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (the Ziprasidone Study Group). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacol. 1999;20:491-505. (Pubitemid 29123876)
18. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;39-44. (Pubitemid 23355888)
19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
20. Heinrichs DW, Hanlon TE, Carpenter WT, Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
21. Andreasen NC, Carpenter WT, Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449. (Pubitemid 40343909)
22. Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993;87:244-252. (Pubitemid 23107274)
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
24. Guy WA. Abnormal Involuntary Movement Scale (AIMS), ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U. S. Department of Health Education and Welfare; 1976.
25. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183. (Pubitemid 13132147)
26. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20):20-27.
27. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101:273-286.
28. Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A double-blind cross-over study. Br J Psychiatry. 1995;166:241-243.
29. Kaptsan A, Dwolatzky T, Lerner V. Ziprasidone-associated depressive state in schizophrenic patients. Clin Neuropharmacol. 2007;30:357-361. (Pubitemid 350307315)
30. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121. (Pubitemid 41773510)